Ketamine Troches for Anxiety Disorders

Anxiety and Ketamine: An Evolving Relationship

Anxiety disorders are among the most common psychiatric conditions worldwide, affecting approximately 18 percent of adults in the United States annually. Despite a range of treatment options — SSRIs, SNRIs, benzodiazepines, buspirone, psychotherapy — a significant subset of patients with anxiety disorders achieve only partial relief or fail to respond to standard treatments.

Ketamine's relationship with anxiety is nuanced: while ketamine can temporarily increase anxiety as a side effect (particularly during onset at higher doses), at therapeutic doses with appropriate preparation, it has demonstrated meaningful anxiolytic effects in clinical settings. For anxiety disorders refractory to conventional treatment, ketamine troches offer a promising avenue. Understanding the safety profile is an important first step for patients considering this option.

Which Anxiety Disorders Respond to Ketamine?

Generalized Anxiety Disorder (GAD)

GAD involves persistent, excessive worry across multiple domains of life, accompanied by physical symptoms (muscle tension, restlessness, difficulty sleeping). The glutamate system plays a significant role in anxiety — hyperactive NMDA signaling in the amygdala and prefrontal cortex is associated with pathological fear and worry.

Ketamine's NMDA receptor blockade modulates this hyperactivity, reducing the neural noise that underlies chronic worry. Observational studies and case series report meaningful reductions in GAD symptoms following ketamine treatment, particularly in patients who haven't responded to SSRIs or SNRIs.

Social Anxiety Disorder (SAD)

Social anxiety involves intense fear of social scrutiny, humiliation, or embarrassment, often leading to significant avoidance of social situations. While formal clinical trials of ketamine specifically for SAD are limited, several mechanisms suggest potential benefit:

• Reduction in threat sensitivity and emotional reactivity
• Modulation of the default mode network, reducing self-referential processing and the self-critical internal monologue characteristic of social anxiety
• Ego-softening effects during sessions that may allow patients to reframe social threat appraisals

PTSD

Post-traumatic stress disorder, while technically a trauma-related disorder rather than purely an anxiety disorder in DSM-5, shares significant overlap with anxiety in its symptom profile. Ketamine's specific mechanisms relevant to PTSD are covered in our article on ketamine troches for PTSD.

Comorbid Anxiety with Depression

The most common clinical presentation for ketamine-treated anxiety is not pure anxiety disorder but anxiety comorbid with depression. Since ketamine's antidepressant effects are well-established, and depression and anxiety commonly co-occur, many patients treated for TRD also report significant improvement in their anxiety symptoms.

Mechanism: How Ketamine Reduces Anxiety

NMDA Receptor Modulation in Fear Circuitry

The amygdala — the brain's threat detection center — expresses high concentrations of NMDA receptors. Pathological anxiety is associated with hyperactivation of amygdala-based fear circuits. Ketamine blocks NMDA receptors, reducing this hyperactivation and potentially disrupting entrenched fear memories.

This is directly analogous to the mechanism proposed for ketamine's effects on PTSD, where fear memory reconsolidation (the updating of fear memories when they are retrieved) may be disrupted or modified by ketamine's NMDA blockade.

Default Mode Network Modulation

The default mode network (DMN) — a set of brain regions active during self-referential thought, rumination, and mind-wandering — is hyperactive in both depression and anxiety. Ketamine disrupts DMN hyperconnectivity, producing the ego-softening and reduced self-referential processing that characterizes its subjective effects.

For anxiety, this disruption may temporarily reduce the capacity for anticipatory worry (which is DMN-mediated) and create a neurobiological opportunity to engage with anxiety from a less reactive stance.

BDNF and Neuroplasticity

As with depression, ketamine's induction of BDNF and subsequent synaptogenesis in prefrontal areas supports top-down regulation of anxiety. The prefrontal cortex normally provides inhibitory control over amygdala reactivity; in chronic anxiety, this top-down regulation is impaired. Ketamine's neuroplastic effects may help restore prefrontal control.

Important Caveat: Ketamine Can Also Increase Anxiety

This is critical for anxiety patients to understand: ketamine at higher doses and particularly during onset can produce or amplify anxiety, dysphoria, and fear. The dissociative effects — loss of familiar sense of self, perceptual distortions, ego dissolution — can be profoundly anxiety-provoking for patients who are not adequately prepared or who are particularly anxious about losing control.

This means:

• Slow titration is especially important for anxiety patients — starting low (50 to 100 mg) and increasing gradually
• Buccal administration may be preferable to sublingual in early sessions for its gentler onset
• Set and setting preparation is even more important for anxiety patients
• A calm, trusted support person during sessions is strongly recommended
• Anxiety management during sessions should be practiced and rehearsed before the first session

Many anxiety patients who initially have difficult onset experiences with ketamine find that with preparation, titration, and practice, the sessions become manageable and the therapeutic benefits emerge.

Clinical Protocols for Anxiety

Assessment

Before starting:

• Complete GAD-7 or DASS-Anxiety at baseline
• Discuss the potential for ketamine to temporarily increase anxiety during sessions
• Review grounding techniques for managing anxiety during onset
• Confirm no history of panic disorder that may predispose to panic attacks during the dissociative state

Starting Dose for Anxiety Patients

Lower starting doses are generally recommended for anxiety patients:

• Initial dose: 50 to 100 mg (more conservative than typical depression starting dose)
• Titration increments: Smaller (25 mg increases rather than 50 mg)
• Target therapeutic range: 150 to 250 mg (often lower than for depression, reflecting greater sensitivity)

Session Frequency

Similar to depression protocols:

• Acute phase: Twice weekly for 4 to 6 weeks
• Maintenance: Weekly to monthly based on response durability

Concurrent Therapy

Anxiety particularly benefits from integration with psychotherapy. Exposure-based therapy (CBT, ACT) conducted during the neuroplasticity window following ketamine sessions can accelerate reduction in avoidance behaviors. Some providers specifically time therapy appointments to occur within 24 to 72 hours of ketamine sessions.

Evidence Overview

Clinical trials specifically targeting anxiety disorders with ketamine are limited compared to TRD, but growing:

• A randomized double-blind trial by Glue et al. (2017) demonstrated that subcutaneous ketamine reduced social anxiety symptoms significantly versus placebo, with effects persisting for 2 weeks
• Observational data from clinical practices consistently shows anxiety improvement accompanying antidepressant response in mixed depression-anxiety patients
• Case series in GAD and PTSD report meaningful responses

Larger controlled trials are ongoing. The mechanistic basis for ketamine's anxiolytic effects is strong, and clinical experience across numerous practices supports its use in treatment-resistant anxiety.

Monitoring Anxiety Response

Track:

• GAD-7 scores at each provider visit
• Session-level anxiety (was the session itself distressing, manageable, or positive?)
• Between-session anxiety trends (are anxiety-free days increasing?)
• Functional markers: Are previously avoided activities being attempted?

Key Takeaways

• Ketamine troches can reduce anxiety in GAD, social anxiety, and comorbid anxiety-depression through NMDA modulation and neuroplastic effects.
• Paradoxically, ketamine can temporarily increase anxiety during sessions — especially at higher doses — requiring careful preparation and titration.
• Start with lower doses (50 to 100 mg) for anxiety patients and titrate more slowly than for pure depression.
• Set, setting, and preparation are especially critical for anxiety patients.
• Combining troche therapy with exposure-based psychotherapy maximizes anxiolytic outcomes.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches